Sam Brusco, Associate Editor09.20.22
Insulet has received a CE mark for its Omnipod 5 automated insulin delivery system for type 1 diabetes patients aged two years and up.
“There is tremendous enthusiasm for Omnipod 5 from the global diabetes community, and we are thrilled to have achieved this latest milestone,” Jim Hollingshead, president and CEO of Insulet told the press. “With Omnipod 5, customers can enjoy the lifestyle benefits of a tubeless, wearable innovation and achieve positive clinical outcomes while managing their diabetes.”
Omnipod 5 is the first CE marked tubeless hybrid closed-loop system that pairs with Dexcom’s G6 continuous glucose monitor (CGM) to automatically adjust insulin and help guard against high and low glucose levels.
Omnipod 5’s SmartAdjust technology receives a CGM value and trend every five minutes to predict where glucose levels will be an hour into the future. The system then increases, decreases, or pauses insulin delivery based on the desired and customized glucose target.
"Today’s announcement is a significant step forward for people in Europe living with diabetes,” said Kevin Sayer, Chairman, president, and CEO of Dexcom. “We’re proud to partner with Insulet, combining our industry-leading Dexcom G6 CGM technology with their tubeless, wearable insulin delivery system, to improve clinical outcomes and reduce the burden of glucose management for people with diabetes.”
Insulet aims to make Omnipod 5 available in select countries beginning in mid-2023.
“There is tremendous enthusiasm for Omnipod 5 from the global diabetes community, and we are thrilled to have achieved this latest milestone,” Jim Hollingshead, president and CEO of Insulet told the press. “With Omnipod 5, customers can enjoy the lifestyle benefits of a tubeless, wearable innovation and achieve positive clinical outcomes while managing their diabetes.”
Omnipod 5 is the first CE marked tubeless hybrid closed-loop system that pairs with Dexcom’s G6 continuous glucose monitor (CGM) to automatically adjust insulin and help guard against high and low glucose levels.
Omnipod 5’s SmartAdjust technology receives a CGM value and trend every five minutes to predict where glucose levels will be an hour into the future. The system then increases, decreases, or pauses insulin delivery based on the desired and customized glucose target.
"Today’s announcement is a significant step forward for people in Europe living with diabetes,” said Kevin Sayer, Chairman, president, and CEO of Dexcom. “We’re proud to partner with Insulet, combining our industry-leading Dexcom G6 CGM technology with their tubeless, wearable insulin delivery system, to improve clinical outcomes and reduce the burden of glucose management for people with diabetes.”
Insulet aims to make Omnipod 5 available in select countries beginning in mid-2023.